Plasma miR-142 predicts major adverse cardiovascular events as an intermediate biomarker of dual antiplatelet therapy

Ítems similars

• Early Dual-Antiplatelet Therapy at the Emergency Department Is Associated with Lower In-Hospital Major Adverse Cardiac Event Risk among Patients with Non-ST-Elevation Myocardial Infarction
  per: Yang, Jen-Han, et al.
  Publicat: (2021)
• Household Air Pollution, Intermediate Outcomes, and Major Adverse Cardiovascular Events
  per: Essouma, Mickael, et al.
  Publicat: (2015)
• Increased Risk for Developing Major Adverse Cardiovascular Events in Stented Chinese Patients Treated with Dual Antiplatelet Therapy after Concomitant Use of the Proton Pump Inhibitor
  per: Zou, Jian-Jun, et al.
  Publicat: (2014)
• Ticagrelor: An investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome
  per: Abergel, Eitan, et al.
  Publicat: (2010)
• Pooled Analysis of Bleeding, Major Adverse Cardiovascular Events, and All‐Cause Mortality in Clinical Trials of Time‐Constrained Dual‐Antiplatelet Therapy After Percutaneous Coronary Intervention
  per: McClure, John D., et al.
  Publicat: (2020)